Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784466 · ClinicalTrials.gov registry record · NA
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
A NA study of Atrial Fibrillation (AF) and Paroxysmal AF, sponsored by Arga Medtech.
- Recruiting
- Registry status
- NA
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06784466 is a NA study of Atrial Fibrillation (AF) and Paroxysmal AF that is actively recruiting participants, run by Arga Medtech. The registered enrollment target is 360 participants, below the 698-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06784466, a NA study of Atrial Fibrillation (AF) and Paroxysmal AF, is actively recruiting participants, sponsored by Arga Medtech.
- RECRUITING
- Registry status
- NA
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.
Conditions Studied
Interventions
- DEVICE Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
Study Locations (20)
Ohio
- TriHealth Cincinnati - Cincinnati
- Cleveland Clinic - Cleveland
- Ohio Health Research and Innovation Institute - Columbus
Other
- AZorg Aalst - Aalst
- Jessa Ziekenhuis - Hasselt
- KBC Split - Split
Georgia
- Emory - Atlanta
- Northside Hospital - Atlanta
Texas
- Texas Cardiac Arrhythmia Research Foundation - Austin
- Methodist - San Antonio
Alabama
- Grandview - Birmingham
Arizona
- Banner University Med Ctr - Phoenix
Arkansas
- Arrhythmia Research Group - Jonesboro
California
- UCSD - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2027-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06784466
The ClinicalTrials.gov registry entry for NCT06784466 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 698-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (48% lower). The listed sponsor is Arga Medtech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention - of which Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System is the first listed.
NCT06784466 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT06784466 about?
NCT06784466 is a clinical study titled "Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation". To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.
What is the current status of trial NCT06784466?
This trial is currently recruiting. It is a NA study. The enrollment target is 360 participants. The study started on 2025-09-10. Estimated completion is 2027-08.
What conditions does trial NCT06784466 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF), Paroxysmal AF, Persistant Atrial Fibrillation.
What interventions are being tested in trial NCT06784466?
The interventions under investigation include: Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System (DEVICE).
Who is sponsoring clinical trial NCT06784466?
This trial is sponsored by Arga Medtech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784466 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
-
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
RECRUITING · NA
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.